RCEL
RCEL
NASDAQ · Biotechnology

Avita Medical Inc

$11.67
-0.17 (-1.44%)
As of Sep 28, 10:21 PM ET ·
Financial Highlights (FY 2026)
Revenue
77.75M
Net Income
-52,748,983
Gross Margin
83.3%
Profit Margin
-67.9%
Rev Growth
+27.7%
D/E Ratio
9.39
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 83.3% 83.3% 48.8% 48.8%
Operating Margin -59.4% -53.5% -12.4% -14.4%
Profit Margin -67.9% -64.5% -9.8% -12.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 77.75M 60.90M 25.19M 23.71M
Gross Profit 64.73M 50.71M 12.30M 11.58M
Operating Income -46,180,940 -32,557,454 -3,131,948 -3,413,299
Net Income -52,748,983 -37,187,909 -2,467,246 -2,847,172
Gross Margin 83.3% 83.3% 48.8% 48.8%
Operating Margin -59.4% -53.5% -12.4% -14.4%
Profit Margin -67.9% -64.5% -9.8% -12.0%
Rev Growth +27.7% +27.7% +20.8% +14.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 161.83M 161.83M 29.07M 27.04M
Total Equity 17.23M 17.23M 72.39M 66.00M
D/E Ratio 9.39 9.39 0.40 0.41
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -43,629,298 -32,467,361 -4,050,890 -3,804,791
Free Cash Flow — — -1,532,934 -2,480,233